

OFFICE 574405

1871 1872 1873 1874 1875 1876 1877 1878 1879 1880 1881 1882 1883 1884 1885 1886 1887 1888 1889 1890 1891 1892 1893 1894 1895 1896 1897 1898 1899 1900 1901 1902 1903 1904 1905 1906 1907 1908 1909 1910 1911 1912 1913 1914 1915 1916 1917 1918 1919 1920 1921 1922 1923 1924 1925 1926 1927 1928 1929 1930 1931 1932 1933 1934 1935 1936 1937 1938 1939 1940 1941 1942 1943 1944 1945 1946 1947 1948 1949 1950 1951 1952 1953 1954 1955 1956 1957 1958 1959 1960 1961 1962 1963 1964 1965 1966 1967 1968 1969 1970 1971 1972 1973 1974 1975 1976 1977 1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 2043 2044 2045 2046 2047 2048 2049 2050 2051 2052 2053 2054 2055 2056 2057 2058 2059 2060 2061 2062 2063 2064 2065 2066 2067 2068 2069 2070 2071 2072 2073 2074 2075 2076 2077 2078 2079 2080 2081 2082 2083 2084 2085 2086 2087 2088 2089 2090 2091 2092 2093 2094 2095 2096 2097 2098 2099 2100 2101 2102 2103 2104 2105 2106 2107 2108 2109 2110 2111 2112 2113 2114 2115 2116 2117 2118 2119 2120 2121 2122 2123 2124 2125 2126 2127 2128 2129 2130 2131 2132 2133 2134 2135 2136 2137 2138 2139 2140 2141 2142 2143 2144 2145 2146 2147 2148 2149 2150 2151 2152 2153 2154 2155 2156 2157 2158 2159 2160 2161 2162 2163 2164 2165 2166 2167 2168 2169 2170 2171 2172 2173 2174 2175 2176 2177 2178 2179 2180 2181 2182 2183 2184 2185 2186 2187 2188 2189 2190 2191 2192 2193 2194 2195 2196 2197 2198 2199 2200 2201 2202 2203 2204 2205 2206 2207 2208 2209 2210 2211 2212 2213 2214 2215 2216 2217 2218 2219 2220 2221 2222 2223 2224 2225 2226 2227 2228 2229 2230 2231 2232 2233 2234 2235 2236 2237 2238 2239 2240 2241 2242 2243 2244 2245 2246 2247 2248 2249 2250 2251 2252 2253 2254 2255 2256 2257 2258 2259 2260 2261 2262 2263 2264 2265 2266 2267 2268 2269 2270 2271 2272 2273 2274 2275 2276 2277 2278 2279 2280 2281 2282 2283 2284 2285 2286 2287 2288 2289 2290 2291 2292 2293 2294 2295 2296 2297 2298 2299 2300 2301 2302 2303 2304 2305 2306 2307 2308 2309 2310 2311 2312 2313 2314 2315 2316 2317 2318 2319 2320 2321 2322 2323 2324 2325 2326 2327 2328 2329 2330 2331 2332 2333 2334 2335 2336 2337 2338 2339 2340 2341 2342 2343 2344 2345 2346 2347 2348 2349 2350 2351 2352 2353 2354 2355 2356 2357 2358 2359 2360 2361 2362 2363 2364 2365 2366 2367 2368 2369 2370 2371 2372 2373 2374 2375 2376 2377 2378 2379 2380 2381 2382 2383 2384 2385 2386 2387 2388 2389 2390 2391 2392 2393 2394 2395 2396 2397 2398 2399 2400 2401 2402 2403 2404 2405 2406 2407 2408 2409 2410 2411 2412 2413 2414 2415 2416 2417 2418 2419 2420 2421 2422 2423 2424 2425 2426 2427 2428 2429 2430 2431 2432 2433 2434 2435 2436 2437 2438 2439 2440 2441 2442 2443 2444 2445 2446 2447 2448 2449 2450 2451 2452 2453 2454 2455 2456 2457 2458 2459 2460 2461 2462 2463 2464 2465 2466 2467 2468 2469 2470 2471 2472 2473 2474 2475 2476 2477 2478 2479 2480 2481 2482 2483 2484 2485 2486 2487 2488 2489 2490 2491 2492 2493 2494 2495 2496 2497 2498 2499 2500 2501 2502 2503 2504 2505 2506 2507 2508 2509 2510 2511 2512 2513 2514 2515 2516 2517 2518 2519 2520 2521 2522 2523 2524 2525 2526 2527 2528 2529 2530 2531 2532 2533 2534 2535 2536 2537 2538 2539 2540 2541 2542 2543 2544 2545 2546 2547 2548 2549 2550 2551 2552 2553 2554 2555 2556 2557 2558 2559 2560 2561 2562 2563 2564 2565 2566 2567 2568 2569 2570 2571 2572 2573 2574 2575 2576 2577 2578 2579 2580 2581 2582 2583 2584 2585 2586 2587 2588 2589 2590 2591 2592 2593 2594 2595 2596 2597 2598 2599 2600 2601 2602 2603 2604 2605 2606 2607 2608 2609 2610 2611 2612 2613 2614 2615 2616 2617 2618 2619 2620 2621 2622 2623 2624 2625 2626 2627 2628 2629 2630 2631 2632 2633 2634 2635 2636 2637 2638 2639 2640 2641 2642 2643 2644 2645 2646 2647 2648 2649 2650 2651 2652 2653 2654 2655 2656 2657 2658 2659 2660 2661 2662 2663 2664 2665 2666 2667 2668 2669 2670 2671 2672 2673 2674 2675 2676 2677 2678 2679 2680 2681 2682 2683 2684 2685 2686 2687 2688 2689



















§ Group Art Unit: Not Yet Assigned  
§  
§ Attorney  
§ Docket: 31689

§ Attorney  
§ Docket: 31689

www

ss

## INFORMATION DISCLOSURE STATEMENT

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

*Martin D. Hooper*

Dated: March 31, 2006

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.A./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	US National Phase of PCT/IL 2004/000898 <b>5</b>
				Filing Date	Herewith
				First Named Inventor	Ehud GAZIT et al
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	1	of	4	Attorney Docket Number	31689

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	1	US-6,359,112	03-19-2002	Kapurniotu et al.	
	2	US-3,791,932	02-12-1974	Schuurs et al.	
	3	US-3,853,987	12-10-1974	Dreyer	
	4	US-4,873,316	10-10-1989	Meade et al.	
	5	US-4,666,828	05-19-1987	Gusella	
	6	US-4,683,202	07-28-1987	Mullis	
	7	US-4,801,531	01-31-1989	Frossard	
	8	US-5,192,659	09-9-1993	Simons	
	9	US-5,272,057	12-21-1993	Smulson et al.	
	10	US-3,839,153	01-1-1974	Schuurs et al.	
	11	US-3,850,752	11-26-1974	Schuurs et al.	
	12	US-3,850,578	11-26-1974	McConnell	
	13	US-3,867,517	02-18-1975	Ling	
	14	US-3,879,262	04-22-1975	Schuurs et al.	
	15	US-3,901,654	08-26-1975	Gross	
	16	US-3,935,074	01-27-1976	Rubenstein et al.	
	17	US-3,984,533	05-5-1976	Uzgiris	
	18	US-3,996,345	07-7-1976	Ullman et al.	
	19	US-4,034,074	05-5-1977	Miles	
	20	US-4,098,876	04-4-1978	Piasio et al.	
	21	US-4,879,219	07-7-1989	Wands et al.	
	22	US-5,011,771	04-30-1991	Bellet et al.	
	23	US-5,281,521	01-25-1994	Trojanowski et al.	
	24	US-6,303,567	10-16-2001	Findeis et al.	
	25	US-2004/0052928	03-18-2004	Gazit	
	26	US-2005/0020809	01-27-2005	Gazit	
	27	US-5,688,561	11-18-1997	Ichikawa et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Documents	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T 6
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
	28	EP 0264166	04-20-1988	Gordon et al.		
	29	PCT WO 2004/052773	06-24-2004	Reches et al.		
	30	PCT WO 2004/060791	07-22-2004	Gazit et al.		
	31	PCT WO 99/58652	11-18-1999	Gerdes et al.		
	32	PCT WO 01/10457	02-15-2001	Vahne		
	33	PCT WO 80/00789	01-1-1980	Chu et al.		
	34	PCT WO 03/063760	07-7-2003	Gazit		
	35	PCT WO 2005/000193	06-6-2005	Gazit		
Examiner Signature					Date Considered	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>		Application Number	US National Phase PCT/IL 2004/000898	
		Filing Date	Herewith	
		First Named Inventor	Ehud GAZIT et al	
		Art Unit	Not Yet Assigned	
		Examiner Name	Not Yet Assigned	
Sheet	2	4	Attorney Docket Number	31689
<b>OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS</b>				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	36	Hartgerink et al. "Self-Assembling Peptide Nanotubes", Journal of the American Chemical Society, 118: 43-50, 1996.		
	37	Ajayan et al. "Applications of Carbon Nanotubes", Topics of Applied Physics, 80: 391-425, 2001.		
	38	Booth et al. "Instability, Unfolding and Aggregation of Human Lysozyme Variants Underlying Amyloid Fibrillogenesis", Nature, 385: 787-793, 1997.		
	39	Glenner "Amyloid Deposits and Amyloidosis. The Beta-Fibrilloses (First of Two Parts)", The New England Journal of Medicine, 302(23): 1283-1292, 1980.		
	40	Ferrannini "Insulin Resistance Versus Insulin Deficiency in Non-Insulin-Dependent Diabetes Mellitus: Problems and Prospects", Endocrine Reviews, 19(4): 477-490, 1998.		
	41	Westermarck "Amyloid and Polypeptide Hormones: What is Their Interrelationship?", Amyloid Int. J. Exp. Clin. Invest, 1: 47-60, 1994.		
	42	Westermarck "Islet Amyloid Polypeptide: Pinpointing Amino Acid Residues Linked to Amyloid Fibril Formation", Proc. Natl. Acad. Sci. USA, 87: 5036-5040, 1990.		
	43	Johnson et al. "Islet Amyloid, Islet-Amyloid Polypeptide, and Diabetes Mellitus", The New England Journal of Medicine, 321(8): 513-518, 1989.		
	44	Mosselman et al. "Islet Amyloid Polipeptide: Identification and Chromosomal Localization of the Human Gene", FEBS Letters, 239(2): 227-232, 1988.		
	45	Moriarty et al. "Effects of Sequential Proline Substitutions on Amyloid Formation by Human Amylin <sub>20-29</sub> ", Biochemistry, 38: 1811-1818, 1999.		
	46	Höppener et al. "Islet Amyloid and Type 2 Diabetes Mellitus", The New England Journal of Medicine, 343(6): 411-419, 2000.		
	47	Seino "S20G Mutation of the Amylin Gene Is Associated With Type II Diabetes in Japanes", Diabetologia, 44: 906-909, 2001.		
	48	Gillmore et al. "Amyloidosis A Review of Recent Diagnostic and Therapeutic Developments", British Journal of Haematology, 99: 245-256, 1997.		
	49	Kulkarni et al. "Investigation of the Effect of Antisense Oligodeoxynucleotides to Islet Amyloid Polypeptide mRNA on Insulin Release, Content and Expression", Journal of Endocrinology, 151: 341-348, 1996.		
	50	Novials et al. "Reduction of Islet Amylin Expression and Basal Secretion by Adenovirus-Mediated Delivery of Amylin Antisense cDNA", Pancreas, 17(2): 182-186, 1998.		
	51	Kahn et al. "Islet Amyloid: A Long-Recognized But Underappreciated Pathological Feature of Type 2 Diabetes", Diabetes, 48: 241-253, 1999.		
	52	Merlini et al. "Intereaction of the Anthracycline 4'-Iodo-4'-Deoxydoxorubicin With Amyloid Fibrils: Inhibition of Amyloidogenesis", Proc. Natl. Acad. Sci. USA, 92: 2959-2963, 1995.		
	53	Soto et al. Beta-Sheet Breaker Peptides Inhibit Fibrillogenesis in A Rat Brain Model of Amyloidosis: Implications for Alzheimer's Therapy", Nature Medicine, 4(7): 822-826, 1998.		
	54	Tenidis et al. "Identification of A Penta- and Hexapeptide of Islet Amyloid Polypeptide (IAPP) With Amyloidogenic and Cytotoxic Properties", Journal of Molecular Biology, 295(4): 1055-1071, 2000.		
	55	Kuner et al. "Controlling Polymerization of Beta-Amyloid and Prion-Derived Peptides With Synthetic Small Molecule Ligands", Journal of Biological Chemistry, 275(3): 1673-1678, 2000.		
	56	Findeis "Approaches to Discovery and Characterization of Inhibitors of Amyloid Beta-Peptide Polymerization", Biochimia & Biophysica Acta, 1502: 76-84, 2000.		

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.A./

57	Wilesmith et al. "Bovine Spongiform Encephalopathy", Current Topics in Microbiology & Immunology, 172: 21-38, 1991.	
58	Gajdusek "Unconventional Viruses and the Origin and Disappearance of Kuru", Science, 197(4307): 943-960, 1977.	
59	Medora et al. "Fatal Familial Insomnia, A Prion Disease With A Mutation at Codon 178 of the Prion Protein Gene", The New England Journal of Medicine, 326(7): 444-449, 1992.	
60	Pinkert et al. "An Albumin Enhancer Located 10 Kb Upstream Functions Along With Its Promoter to Direct Efficient, Liver-Specific Expression in Transgenic Mice", Genes & Development, 1: 268-276, 1987.	
61	Calame et al. "Transcriptional Controlling Elements in the Immunoglobulin and T Cell Receptor Loci", Advances in Immunology, 43: 235-275, 1988.	
62	Winoto et al. "A Novel, Inducible and T Cell-Specific Enhancer Located at the 3' End of the T Cell Receptor Alpha Locus", The EMBO Journal, 8(3): 729-733, 1989.	
63	Banerji et al. "A Lymphocyte-Specific Cellular Enhancer Is Located Downstream of the Joining Region in Immunoglobulin Heavy Chain Genes", Cell, 33: 729-740, 1983.	
64	Byrne et al. "Multiplex Gene Regulation: A Two-Tiered Approach to Transgene Regulation in Transgenic Mice", Proc. Natl. Acad. Sci. USA, 86: 5473-5477, 1989.	
65	Edlund et al. "Cell-Specific Expression of the Rat Insuline Gene: Evidence for Role of Two Distinct 5' Flanking Elements", Science, 230(4278): 912-916, 1985.	
66	Bursavich et al. "Designing Non-Peptide Peptidomimetics in the 21st Century: Inhibitors Targeting Conformational Ensembles", Journal of Medical Chemistry, 45(3): 541-558, 2002.	
67	Baltzer et al. "De Novo Design of Proteins - What Are the Rules?", Chem. Rev., 101(10): 3153-3163, 2001.	
68	Orlandi et al. "Cloning Immunoglobulin Variable Domains for Expression by the Polymerase Chain Reaction", Proc. Natl. Acad. Sci. USA, 86: 3833-3837, 1989.	
69	Winter et al. "Man-Made Antibodies", Nature, 349: 293-299, 1991.	
70	Kohler et al. "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity", Nature, 256: 495-497, 1975.	
71	Kozbor et al. "Specific Immunoglobulin Production and Enhanced Tumorigenicity Following Ascites Growth of Human Hybridomas", Journal of Immunological Methods, 81: 31-42, 1985.	
72	Cote et al. "Generation of Human Monoclonal Antibodies Reactive With Cellular Antigens", Proc. Natl. Acad. Sci. USA, 80: 2026-2030, 1983.	
73	Cole et al. "Human Monoclonal Antibodies", Molecular & Cellular Biochemistry, 62(2): 109-120, 1984.	
74	Han et al. "Technetium Complexes for the Quantitation of Brain Amyloid", J. Am. Chem. Soc., 118: 4506-4507, 1996.	
75	Sambrook et al. "Molecular Cloning: A Laboratory Manual", 2nd Edition, Cold Spring Harbor Laboratory, 1989.	
76	Ausubel et al. Current Protocols in Molecular Biology, 1 (Suppl.63).	
77	Perbal "A Practical Guide to Molecular Cloning", Wiley-Interscience Publication.	
78	Stites et al. Basic & Clinical Immunology, 8th Edition.	
79	Gait "Oligonucleotide Synthesis - A Practical Approach", IRL Press.	
80	Freshney "Animal Cell Culture - A Practical Approach", IRL Press.	
81	Marshak et al. "Strategies for Protein Purification and Characterization, A Laboratory Course Manual", Cold Spring Harbor Laboratory Press, 1996.	
82	Cooper "Selective Amyloid Staining As A Function of Amyloid Composition and Structure. Histochemical Analysis of the Alkaline Congo Red. Standardized Toluidine Blue, and Iodine Methods", Laboratory Investigation, 31(3): 232-238, 1974.	
83	Gorman et al. "Alzheimer $\beta$ -Amyloid Peptides, Structures Of Amyloid Fibrils and Alternate Aggregation Products", Biopolymers, 60: 381-394, 2001. Claims: 1-16, 22-26, 70-80, 91-100.	
84	Kapurniotu et al. DATABASE, Accession No. AAW93015, 1991. Claims: 1-16, 22-26.	
85	Hoeppener et al. "The Complete Islet Amyloid Polypeptide Precursor Is Encoded by Two Exons", Biochem. Biophys. Res. Commun., 189: 1569-1577, 1993. DATABASE, Accession No. S04016, 1993. Claims: 1-16, 22-26.	
86	Stephenson et al. "The 'Promiscuous Drug Concept' With Applications to Alzheimer's Disease", FEBS Letters, 579: 1338-1342, 2005.	
87	Hayden et al. "'A' Is for Amylin and Amyloid in Type 2 Diabetes Mellitus", JOP. J. Pancreas (Online), 2(4): 124-139, 2001.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.A./

88	Grady et al. "Axe-Txe, A Broad-Spectrum Proteic Toxin-Antitoxin System Specified by A Multidrug-Resistant, Clinical Isolate of Enterococcus Faecium", Molecular Biology, 47(5): 1419-1432, 2003. Abstract, P.1424, Col.1/P.1426, Col.2, Fig.5	10/19/05 4405
89	Cherny et al. "The YefM Antitoxin Defines A Family of Natively Unfolded Proteins", The Journal of Biological Chemistry, 279(9): 8252-8261, 2004.	
90	Engelberg-Kulka et al. "Bacterial Programmed Cell Death Systems as Targets for Antibiotics", Trends in Microbiology, 12(2): 66-71, 2004.	
91	Forloni et al. "Anti-Amyloidogenic Activity of Tetracyclines: Studies In Vitro", FEBS Letters, 487(3): 404-407, 2001. Abstract, Results, Figs.1, 3.	
92	Lansbury Jr. "Following Nature's Anti-Amyloid Strategy", Nature Biotechnology, 19(2): 112-113, 2001.	
93	Grateau "Le Curli du Coli: Une Variété Physiologique d'Amylose", Medecine Sciences, 18(6-7): 664, 2002.	
94	Cherny et al. "The Formation of Escherichia Coli Curli Amyloid Fibrils Is Mediated by Prion-Like Peptide Repeats", Journal of Molecular Biology, 352(2): 245-252, 2005.	
95	Görbitz "Nanotube Formation by Hydrophobic Dipeptides", Chemistry, 7(23): 5153-5159, 2001.	
96	Reches et al. "Amyloid Fibril Formation by Pentapeptide and Tetrapeptide Fragments of Human Calcitonin", Journal of Biological Chemistry, 277(38): 35475-35480, 2002.	
97	Halder et al. "First Crystallographic Signature of the Highly Ordered Supramolecular Helical Assemblage From A Tripeptide Containing A Non-Coded Amino Acid", Tetrahedron Letters, 43(14): 2653-2656, 2002.	
98	Maji et al. "Fibril-Forming Model Synthetic Peptides Containing 3-Aminophenylacetic Acid", Tetrahedron, 58(43): 8695-8702, 2002.	
99	Hartgerink et al. "Peptide Nanotubes and Beyond", Chemistry, A European Journal, 4(8): 1367-1372, 1998.	
100	Ghadiri et al. "Self-Assembling Organic Nanotubes Based on A Cyclic Peptide Architecture", Nature, 366: 324-327, 1993.	
101	Horne et al. "A Heterocyclic Peptide Nanotube", Journal of the American Chemical Society, 125(31): 9372-9376, 2003.	
102	Reches et al. "Casting Metal Nanowires Within Discrete Self-Assembled Peptide Nanotubes", Science, 300(5619): 625-627, 2003.	
103	Adekore et al. "Carbon Nanotubes", P.1-11, 2001.	
104	Brauer "GB-245 Nanotubes: Directions and Techno", BCC, P.1-14, 2000.	
105	Martin et al. "The Emerging Field of Nanotube Biotechnology", Nature Reviews, 2: 29-37, 2003.	
106	Zhang et al. "Design of Nanostructured Biological Materials Through Self-Assembly of Peptides and Proteins", Current Opinion in Chemical Biology, 6: 865-871, 2002.	
107	Daenen et al. "The Wondrous World of Carbon Nanotubes", P.1-8, 2003.	
108	Gazit "Global Analysis of Tandem Aromatic Optapeptide Repeats: The Significance of the Aromatic-Glycine Motif", Bioinformatics Discovery Note, 18(6): 880-883, 2002.	
109	Gazit "The 'Correctly Folded' State of Proteins: Is it a Metastable State ?", Angew. Chem. Int. Ed., 41(2): 257-259, 2002.	
110	Gazit "A Possible Role for 'Phi'-Stacking in the Self-Assembly of Amyloid Fibrils", FASEB: 77-83, 2002.	
111	Coughlan et al. "Factors Influencing the Processing and Function of the Amyloid Beta Precursor Protein - A Potential Therapeutic Target in Alzheimer's Disease?", Pharmacology and Therapeutics, 86: 111-144, 2000.	
112	Damas et al. "Review: TTR Amyloidosis - Structural Features Leading to Protein Aggregation and Their Implications on Therapeutic Strategies", Journal of Structural Biology, 130: 290-299, 2000.	
113	Gazit "Mechanistic Studies of the Process of Amyloid Fibrils Formation by the Use of Peptide Fragments and Analogues: Implications of the Design of Fibrillation Inhibitors", Current Medicinal Chemistry, 9: 1667-1675, 2002.	
114	Mazor et al. "Identification and Characterization of A Novel Molecular-Recognition and Self-Assembly Domain Within the Islet Amyloid Polypeptide", Journal of Molecular Biology, 322: 1013-1024, 2002.	

Signature	/Nina Archie/	Considered	11/20/2008
-----------	---------------	------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>. Applicant's unique citation designation number (optional). <sup>2</sup>. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.A./